Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23092850 | 0.86 | MEN1 (0.44) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL9724933 | 0.86 | MEN1 (0.42) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL20548080 | 0.85 | KMT2A (0.41) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL12221438 | 0.83 | MEN1 (0.46) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1933912 | 0.83 | MEN1 (0.49) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL21657581 | 0.82 | MEN1 (0.48) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL31255467 | 0.81 | MEN1 (0.42) | MEN1KMT2ANPC1RAB9AKDM4C | |
| SCHEMBL5211517 | 0.81 | KMT2A (0.48) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1516089 | 0.81 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL7939089 | 0.80 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139294-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20230167084-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| EP-4139294-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4x Discovery Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667243-A | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021214470-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167084-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | MEN1 4307/4885KMT2A 1158/4885ALDH1A1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.